EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA

这是一项在转移性肾癌患者中使用表皮生长因子受体(EGFR)抗体的II期临床试验。这项研究的主要目标是确定在开始使用C225治疗后，当给予两周一次的静脉输液时，该患者群体的进展时间是否从4个月增加到8个月。54名患者参加了这项研究(一名患者来自UAB，原因是管理问题)。完成1个疗程的患者的病情进展时间从98天到332天不等。记录到一例部分反应和两例轻微反应。主要不良反应为皮肤毒性3级，表现为毛囊皮疹和指甲改变，停药后完全消失。

This is a phase II clinical trial using an antibody to the epidermal growth factor receptor (EGFR) in patients with metastatic renal cell carcinoma. The primary objective of the study was to determine whether the time to progression in this patient population is doubled from 4 months to 8 months following the initiation of treatment with C225 when administered biweekly intravenous infusions. Fifty-four patients were enrolled in this study (one from UAB, because of administrative issues). Time to progression for patients completing = 1 course of therapy ranges from 98 to 332 days. One partial and two minor responses were recorded. The primary side effects were grade = 3 skin toxicities manifested as follicular rash and nail had changes, which fully resolve after cessation of treatment